partly polymeric [2, 3] . Immunoglobulins are glycoproteins: recently we, and others, have described abnormal Background. Reduced galactosylation of the O-linked glycans of the IgA1 hinge region in IgAN has recently carbohydrate composition within the IgA1 molecule in IgAN, which may be of pathogenic significance [4] [5] [6] [7] . been described. To investigate the underlying defect resulting in this abnormality, we have measured the Protein glycosylation occurs in two major forms, Nand O-linked; these glycan types and biochemical activity of b1,3 galactosyltransferase, the enzyme responsible for galactosylation of O-linked sugars.
Introduction [12, 13] . The O-linked sugars of IgA1 are apparently abnormal in IgAN. We, and others, have reported IgA nephropathy (IgAN ) is the commonest form of reduced binding of IgA1 to jacalin, a lectin which glomerulonephritis in developed countries, and a signi-recognizes Gal b1,3GalNAc [4, 5] , increased binding ficant proportion of patients will progress to end stage to lectins which recognize terminal GalNAc [7 ] , and renal failure [1] . The diagnostic hallmark of the condi-reduced total Gal content of IgA1 [5 ] . The most tion is deposition of IgA in the glomerular mesangium; consistent explanation of these findings is reduced this is known to be of the IgA1 subclass and at least galactosylation of the O-linked sugars of the IgA1 hinge region, leading to expression of truncated moiet-at 500 g. The plasma samples were clotted by the addition rather than degradative, since C1 inhibitor, another of of 0.5 g/ml protamine sulphate and 0.5 U/ml bovine thromthe few serum proteins with O-glycosylation, does not bin, serum separated after centrifugation at 1000 g, and display the same pattern of lectin binding as IgA1 in frozen in aliquots at −20°C. The plasma volume removed IgAN [7 ] .
from the blood cells was replaced with buffered Hank's Galactosylation of O-linked sugars is effected by balanced salt solution ( HBSS) (Life Technologies, Paisley, the intracellular enzyme b1,3 galactosyltransferase UK ), and peripheral blood mononuclear cells (PBMCs) ( b1,3GT ). This enzyme catalyses the transfer of galac-separated by density gradient centrifugation on Ficoll 400, tose from the nucleotide donor, uridine 5' diphospho-density 1.077 (Histopaque; Sigma Chemical Co, Poole, UK ). galactose ( UDP-Gal), to the acceptor, GalNAc The PBMCs were washed three times in HBSS and resus-O-linked to serine residues in the IgA1 hinge region: pended in 10 ml HBSS containing 1% foetal calf serum (FCS ) ( HBSS/FCS ). The cells were fractionated into monoAcceptor Donor Product cyte, T, and B cell populations using anti-CD14, CD2, and CD19-conjugated magnetic beads ( Dynabeads; Dynal Ltd,
b1,3GT
Wirral, UK ) in a sequential fashion. The cell populations were washed in serum-free HBSS, pelleted by centrifugation GalNAc-a1,3-Ser + UDP-Gal Gal-b1,3-GalNAc-a1,3Ser
and lysed by detergent treatment with 1 ml 0.5% Nonidet P40 in phosphate buffered saline (PBS ), sonicated three b1,3GT has yet to be isolated or cloned, but its times, and frozen in aliquots at −70°C. The purity of the functional activity may be measured by the detection harvested cell populations was >90% by immunocytochemiof increased galactosylation of a suitable acceptor cal staining of cytocentrifuge preparations. substrate. Glycosyltransferases show exquisite specifi-A standard cell lysate was also prepared in the same way city with respect to the monosaccharide donor, and from unfractionated peripheral blood mononuclear cells can also be highly selective as to the acceptor; this pooled from four normal individuals. Protein content of the latter selectivity may be influenced by the oligosacchar-lysate samples was measured (Bio-Rad DC Protein Assay;
Bio-Rad Ltd, Hemel Hempstead, UK ).
ide chain and by the peptide backbone [14 ] . For this reason, the b1,3GT assay system developed for the experiments described in this study employed an Preparation of acceptor substrate for measurement of acceptor derived from IgA1 hinge regions. Altered b1,3GT activity IgA1 hinge region O-glycosylation in IgAN can be detected by the differential binding of lectins with Serum from six normal individuals was pooled and a crude immunoglobulin fraction prepared by precipitation with 20% specificity for the various glycans. In previous studies polyethylene glycol 6000. The precipitate was redissolved in [7 ] we have demonstrated increased terminal GalNAc [15, 16 ] . In the study now reported, increases in galacto-overnight at 37°C with pepsin at 1550 w/w. The protein sylation of the acceptor after incubation with cell-digest was passed through a Sephadex G10 column to lysate associated b1,3GT were detected by reduced exchange the buffer to 0.175M Tris-HCl buffer, pH 7.5, and binding of this lectin. The assay was carried out using the O-glycosylated peptide fragments isolated on jacalinan ELISA-type system, coating immunoplates with the conjugated agarose ( Vector Ltd, Peterborough, UK), removIgA1-derived acceptor to tailor the assay to ing unbound proteins with three washes in excess Tris-HCl.
Bound fragments were eluted from the jacalin-agarose with IgA1-galactosylating activity as much as possible. This were removed by centrifugation and the acceptor preparation again passed through a Sephadex G10 column in PBS, adjusted to a total protein concentration of 100 mg/ml, and
Subjects and methods
frozen in aliquots at −70°C.
Subjects b1,3GT assay 120 ml venous blood was obtained from nine patients with biopsy-proven IgAN (six male, mean age 33 years, range 96-well immunoplates ( ICN Flow Ltd, Rickmansworth, UK ) 23-51 years), and 12 normal individuals with no known were coated with 50 ml/well of the acceptor preparation renal or systemic disease (six male, mean age 38 years, range overnight at 4°C, and washed four times in PBS. This 20-64 years). These studies were approved by the Ethical washing step was repeated between each stage of the assay. Committee of Leicestershire Health Authority. The cell lysate samples were thawed rapidly, diluted in PBS to approximately 250 mg/ml, and duplicate 30 ml aliquots applied to the wells. 10 ml/well 4× concentration reaction
Serum samples and cell lysates
buffer (1 mM UDP-Gal/80mM CaCl 2 in PBS) was added. Blank (no lysate) wells containing 30 ml PBS and 10 ml 4× The blood samples were taken into preservative-free heparin ( 10 U/ml blood) and the plasma separated by centrifugation reaction buffer alone, and a series of 11 doubling dilutions b1,3 galactosyltransferase in IgAN 703 of the standard cell lysate forming a standard curve ( protein tests, as were the lectin binding results of serum IgA. Linear range 20 mg/ml to 5 mg/ml ) were set up on each plate. The regression analysis was carried out to investigate the relationplates were sealed and incubated overnight (18 h) at 37°C. ships between b1,3GT activity of each cell type and lectin After further washing, the binding of the GalNAc-specific binding of serum IgA from the same subject in IgAN and lectin Vicia villosa ( VV ) to the acceptor was measured. controls. Results quoted in the text are mean values of IgAN 40 ml/well biotinylated VV lectin ( Vector Ltd ) at 1 mg/ml in or control groups, ±SEM. PBS was applied to the plates for 90 min at room temperature, followed by 40 ml/well horseradish peroxidase-Results conjugated avidin D ( Vector Ltd ) at 2.5 mg/ml for 90 min at room temperature. lysate reduced the VV binding of the acceptor; the Calculation of b1,3GT activity in cell lysates degree of this reduction was proportional to the protein concentration of this lysate over a range of The degalactosylated acceptor coated on to the immunoplates 80-1200 mg/ml. The standard was assigned a b1,3GT expressed a high level of terminal GalNAc moieties, and activity of 105 AU and a series of doubling dilutions consequently showed high binding to the GalNAc-specific set up on each assay plate to allow the conversion of VV lectin. Incubation with cell lysates resulted in subtracted OD values of test lysate samples to AU/mg re-galactosylation of some of the moieties by the action of protein. The enzyme activity was shown to be time b1,3GT, with a corresponding reduction in VV-binding proand temperature dependent, and the lectin binding of portional to the enzyme activity. Therefore, the OD value of the acceptor was unaffected by incubation with irrelevthe wells were subtracted from that of the blank (no lysate) ant proteins or lysates of non-viable cells over the for each plate. Standard curves were constructed from the subtracted ODs of a series of doubling dilutions of the same concentration range as the standard lysate, or by standard lysate, which was assigned a b1,3GT activity of 105 b1,4 galactosyltransferase at a concentration range of AU at its neat concentration. b1,3GT activity values for the 0.01-100 mU/ml. Bovine serum albumin, a nontest lysates were then read from the standard curve. The glycosylated protein, and IgG, which carries similar actual measured protein values of the lysate dilutions were N-linked carbohydrate moieties as IgA1, but which used to express the results as AU/mg total lysate protein. lectin. 5 ml serum samples were diluted with an equal volume >20mM concentrations of galactose, glucose, or of PBS and a crude high molecular weight protein fraction N-acetylglucosamine all failed to produce 50% inhibiprepared by precipitation with 2.8 g ammonium sulphate. tion. 0.5 mM GalNAc gave 80% inhibition of VV The precipitates were redissolved in PBS and twice passed binding to the acceptor, galactose gave 14% inhibition through Sephadex G25 columns. 96-well immunoplates were and N-acetyl glucosamine failed to inhibit at all at this coated with 100 ml/well rabbit anti-human IgA ( Dako Ltd, concentration. These observations are entirely consistent High Wycombe, UK ) at 10 mg/ml in 0.05 M carbonate/ with the reported specificity of VV lectin for GalNAc bicarbonate buffer, pH 9.6 overnight at 4°C, washed four [15, 16 ] .
times in PBS and the excess protein binding sites blocked with 100 ml/well oxidized glutathione at 2 mg/ml in PBS.
b1,3GT activity in IgAN and controls
Ammonium sulphate precipitate samples adjusted to 3 mg/ml were applied at 50 ml/well in duplicate and incubated over-PBMCs from nine patients with IgAN and 12 controls night at 4°C; this concentration had previously been shown were fractionated into their constituent cell pop- mg, control 8.7±1.14 AU/mg), as shown in Figure 1 . However, the B cell lysates from patients with IgAN Statistical analysis had significantly lower b1,3GT activity than those of controls ( IgAN 6.2±0.71 AU/mg, control 9.5±1.03
b1,3GT activities of T cell, B cell and monocyte lysates in IgAN and controls were compared by unpaired Student t-AU/mg, P=0.018) ( Figure 2 ). Fig. 3 . VV lectin binding of antibody-immobilized serum IgA from Fig. 1 . b1,3GT activity of T cell and monocyte lysates in patients with IgAN (2 ) and controls (#). There was no difference in the patients with IgAN (2) and controls (#). In IgAN, IgA shows significantly higher lectin binding than control (P=0.007). enzyme activity of either cell type between the two groups of subjects. VV lectin binds to terminal O-linked GalNAc, and increased binding of this lectin to IgA1 is seen in IgAN such relationship was seen in the control subjects (r= [7 ] , probably indicating reduced galactosylation of the 0.200, P=NS ). hinge region sugars. In agreement with our previous report involving a larger cohort of subjects [7 ] , antibody-immobilized serum IgA displayed significantly Discussion higher VV lectin binding in the current group of patients with IgAN than in the controls (OD at 492nm:
The O-glycosylation defect of IgA1 in IgAN has not IgAN 0.2±0.02; control 0.10±0.02, P=0.007) been fully characterized. Reports of increased binding ( Figure 3) .
to lectins with affinity for terminal GalNAc [7] and reduced binding to jacalin, a lectin with affinity for Relationship between cellular b1,3GT activity and VV galactosylated Gal b1,3GalNAc [4, 5] , indicate that it lectin binding of serum IgA1 may take the form of a lack of terminal galactosylation of O-linked moieties, though other investigators report Linear regression analysis was carried out to look for relationships between the b1,3GT activities of each cell increased binding of IgA1 to jacalin in IgAN (17,18) .
These findings all demonstrate that the O-glycans of type and the O-galactosylation status of IgA1 as assessed by VV lectin binding in IgAN and controls. IgA1 in IgAN are indeed abnormal, and their conflicting nature stresses the importance of further work IgA1 lectin binding was unrelated to T cell or monocyte enzyme activity in both the IgAN and the control to clarify the exact biochemical defect involved.
The experiments described in this study attempted groups (data not shown). In IgAN, B cell b1,3GT activity had a strong inverse correlation with IgA1 to investigate the activity of the enzyme responsible for galactosylation of O-linked glycans in peripheral lectin binding (r=-0.872, P=0.002) ( Figure 4 [21, 22] . The abnormality results from the loss of b1,3 galactosyltransferase activity in the tosylated IgA1 as the acceptor substrate to tailor the system as closely as possible to the in vivo situation. affected cells [23, 24] . The mechanism behind this is unknown, but is due to repression of a functional gene Increases in terminal glycosylation were detected by reduction of VV lectin binding to exposed GalNAc rather than a mutation [25 ] . The O-linked sugars of IgA1 are identical to the T antigen, and the abnormalunits. This is assumed to be due to the enzymatic addition of b1,3-linked galactose, as this is the linkage ity affecting them in IgAN is apparently also a truncation resulting in the expression of terminal GalNAc, usually found in O-glycans. It is possible that other glycosyltransferases may also be acting upon the sub-the Tn antigen. The finding of reduced B cell b1,3GT activity in IgAN reported here adds to the similarities strate in this assay system, though in control experiments, b1,4 galactosyltransferase did not affect the VV between the O-glycosylation defects seen in the Tn syndrome and IgAN. lectin binding of the acceptor. Structural analysis of the acceptor sugars would be necessary to demonstrate
The O-linked carbohydrate moieties of the IgA1 hinge region constititute the preferred recognition that the change in VV binding is entirely due to b1,3GT activity. However, the action detected in this assay motif of the hepatic ASGPR, and therefore are crucial to its handling in vivo, since this is the major catabolic system does mimic the abnormality of serum IgA1 described in IgAN, the precise nature of which has pathway of IgA1 [9 ] . This has important implications, since increased serum levels of IgA1 in IgAN may not also yet to be confirmed. The results of this study show that B cell lysates from patients with IgAN have be entirely attributable to increased production, but also to decreased clearance. reduced ability to reglycosylate the IgA1-derived acceptor, and this is interpreted as reduced B cell
The CH2 domain of the Fc region of antibody molecules is important in effector functions, since the b1,3GT activity. This finding supports the hypothesis that increased GalNAc expression by IgA1 is indeed Fca receptor and complement binding sites are located
here [11] . The O-linked carbohydrates of IgA1 are due to the failure of full galactosylation of these moieties to produce the usual Gal b1,3GalNAc form. adjacent to this region, and appear to be involved in the interaction with leucocyte Fca receptors ( FcaRs) Furthermore, the activity of this galactosylating enzyme in B cells showed a significant negative correla- [10] . This may be because the glycans are actually part of the recognition motif, or because their presence is tion with terminal GalNAc expression of serum IgA1 as judged by VV lectin binding in patients with IgAN, required to confer a molecular structure which renders the ligand accessible and recognizable to the receptor. suggesting a causal relationship. No such relationship was seen in controls; presumably the control IgA1 is Human mesangial cells have recently been shown to express an FcaR [26, 27] , and though this is as yet fully galactosylated in all the available sites, and its lectin binding is not therefore related to the limiting uncharacterized, and its ligand undefined, it may be that the O-linked glycans of IgA1 could affect its factor of enzyme activity. The assay employed in this study cannot indicate whether the functional deficiency interaction with this receptor. This may provide a pathway by which deposited IgA1 results in glomerular reflects low levels of enzyme, or some abnormality which compromises its activity. Further elucidation injury, since ligation of both leucocyte and mesangial
Fc receptors leads to cell activation and initiation of awaits isolation of the enzyme and cloning of the gene.
Protein glycosylation defects are increasingly recog-inflammatory events. The abnormality of IgA1 O-linked glycosylation in nized in disease states. One well described example is that of IgG in autoimmune rheumatoid disease. In this IgAN is inferred from altered lectin binding potential.
The same mechanism could influence binding to other case, there is a failure of terminal galactosylation of N-linked moieties [19 ] , which has been shown to be proteins in vivo, promoting non-immunological complex formation, and accounting for the increased levels due to reduced activity of the N-galactosylating enzyme b1,4 galactosyltranferase in B cells [20] . T cell and of IgA complexes described in the serum of the patients [28, 29] . It is also possible that binding to mesangial monocyte enzyme activity is normal. Though the intracellular processes involved in N-and O-linked matrix components may be enhanced by lectin-like interactions. If altered O-glycosylation affects the strucglycosylation of nascent proteins are distinct from one another, the parallels between this defect and that of ture of the IgA1 hinge region, possibly shortening it, antibody-antigen binding may be affected by steric IgA1 in IgAN are intriguing. Few serum proteins carry O-linked sugars. IgAN is the first condition in which hindrance resulting from the proximity of the rest of the IgA1 molecule: low IgA affinity has indeed been an abnormality of O-linked glycans in a serum protein has been described. However, some membrane proteins described in IgAN [30 ] .
The reduced B cell b1,3GT activity reported in this are highly O-glycosylated, and disease-associated defects in these are known. One example is the rare study provides an explanation for the abnormality of O-linked glycosylation of serum IgA1 recently deshaematological disorder, the Tn polyagglutinability syndrome. When displayed by membrane proteins, cribed in IgAN. This may prove to be a defect fundamental the pathogenesis of IgAN. The sequence of Galb1,3GalNAc is known as the Thomsen-Freidenrich ( T ) antigen, and the abnormal agalactosyl form, con-b1,3GT is still unknown. Once established, it will A. C. Allen et al. 706 lectins from Vicia villosa. Two distinct carbohydrate binding facilitate future studies to define the molecular nature activities are present in seed extracts. J Biol Chem 1983; 258: of this b1,3GT deficiency and its tissue distribution. 5165-5171 16. Osawa T, Tsuji T. Fractionation and structural assessment of
